Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.67 |
| ▸ | MMP9 | P14780 | 9/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.67 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | MMP1 | P03956 | 1/20 | 0.60 |
| ▸ | MMP3 | P08254 | 1/20 | 0.60 |
| ▸ | MMP7 | P09237 | 1/20 | 0.60 |
| ▸ | MMP13 | P45452 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697591 | 0.87 | MMP2 (0.85) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL697592 | 0.87 | MMP2 (0.85) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL4188026 | 0.87 | MMP2 (0.85) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL11950580 | 0.85 | POLB (0.65) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL11952565 | 0.85 | POLB (0.65) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL6774068 | 0.85 | BACE1 (0.67) | MMP2MMP9POLBADAMTS4ALDH1A1 | |
| SCHEMBL8912956 | 0.85 | L3MBTL1 (0.78) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL15682738 | 0.84 | MMP2 (0.71) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL15682728 | 0.84 | MMP2 (0.71) | MMP2MMP9POLBADAMTS4ADAMTS5 | |
| SCHEMBL6771004 | 0.83 | ADAMTS4 (0.51) | MMP2MMP9POLBADAMTS4MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | MMP2 2769/4885MMP9 1577/4885POLB 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.